Scoop: CNS biotech Map­Light Ther­a­peu­tics eyes $175M raise for PhII clin­i­cal tri­als in schiz­o­phre­nia, autism and Parkin­son's

Map­Light Ther­a­peu­tics, a biotech fo­cused on cen­tral ner­vous sys­tem dis­or­ders, is eye­ing a large $175 mil­lion fi­nanc­ing as it beefs up the C-suite and ad­vances …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER